Drug Approval Package
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drug Approval Package

  • Print
  • Share
  • E-mail
-

Zyprexa Relprevv (olanzapine) for Extended Release Injectable Suspension 210 mg, 300 mg, and 405 mg
Company: Eli Lilly and Company
Application No.: 022173
Approval Date: 12/11/2009

Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance.

 

Date created: July 27, 2010

Back to Top    Drugs@FDA

Vision impaired people having problems accessing certain pages of a PDF file may call (301) 796-3634 for assistance.

Note: Documents in PDF format require the Adobe Acrobat Reader®.

-
-